A $35 Billion Market
Looking for a Real Answer
By 2025, over one billion women globally have reached menopause. In the United States alone, approximately 1.3 million women enter menopause every year, and the perimenopause transition — which can begin a decade earlier — affects tens of millions more. The global menopause market was valued at $21.4 billion in 2025 and is projected to reach $35.6 billion by 2032, growing at 7.5% CAGR.
Despite this scale, the majority of women navigating this transition report that existing solutions are inadequate. Hormone replacement therapy carries well-documented risks and contraindications. Over-the-counter supplements are largely underdosed and poorly absorbed. The pharmaceutical industry has historically underinvested in women's hormonal health relative to the size and severity of the need.
Perimenopause is now being called the next major frontier in women's health investment. Major media, celebrity advocacy, and a wave of femtech innovation are all converging on this space at the same moment. The demand is enormous and underserved. The timing has never been better.
Perimenopause is the new frontier. Capital is following.
In September 2025, STAT News identified perimenopause as the fastest-growing category in women's health investment. Hims and Hers launched a dedicated perimenopause treatment line in October 2025. Flo Health launched its Perimenopause Score across both major app platforms. Private equity and venture capital are entering this space in force. Sovereign ECS enters at the right moment — with a formulation, delivery mechanism, and membership model that none of these new entrants can replicate.
What Women Are Being
Offered Is Not Enough
The conventional response to perimenopause and menopause has been fragmented, inadequate, and in many cases inaccessible. Hormone replacement therapy carries significant risk profiles and is contraindicated for large portions of the target population. Low-dose OTC supplements suffer from poor bioavailability and inconsistent efficacy. The wellness industry's offerings have been largely single-symptom, single-product, and disconnected from the whole-body biology of this transition.
What women actually need is a solution that addresses the underlying regulatory system — not just the surface symptoms. One that is natural, THC-free, non-hormonal, and genuinely bioavailable. One embedded in a broader support ecosystem that recognises the emotional, spiritual, nutritional, and physiological complexity of this transition. Nothing in the current market offers all of this in a single coherent platform.
The gap is structural, not marginal. Existing CBD suppository products on the market use CBD-only or low-dose formulations that do not activate the full endocannabinoid system. Sovereign ECS deploys a broad-spectrum formulation at 120 to 150mg per unit, sitting at the centre of a membership platform. That combination does not currently exist anywhere in the market.
The System Inside Every Woman
That Medicine Forgot
Inside every human body is a biological network that most women — and most doctors — have never been told about. It is called the endocannabinoid system, or ECS. It is one of the most widespread receptor networks in the human body, with receptors found throughout the brain, nervous system, immune tissue, reproductive organs, skin, and gut. Its primary function is homeostasis — the continuous work of keeping the body in balance.
During perimenopause and menopause, estrogen and progesterone levels fluctuate and decline — and these hormones interact directly with ECS receptor expression. As hormone levels shift, ECS function becomes dysregulated, contributing directly to the full spectrum of symptoms women experience. Supporting the ECS during this transition is not about replacing hormones. It is about restoring the body's own natural regulatory capacity.
Suppository delivery bypasses first-pass liver metabolism, delivering phytocannabinoids directly to the pelvic region where CB1 and CB2 receptors are densely expressed in the uterus, ovaries, and surrounding tissue. Bioavailability of 70 to 90% versus 6 to 20% for oral CBD products.
The 12-cannabinoid Sovereign ECS formulation — CBD, CBDA, CBG, CBGA, CBN, CBL, and additional minor cannabinoids — activates both CB1 and CB2 receptors simultaneously. Single-compound CBD isolate products activate neither receptor directly. The difference in therapeutic scope is categorical, not incremental.
THC-free, non-psychoactive, and entirely free of synthetic hormones. Broad-spectrum hemp-derived phytocannabinoids only. Safe for women who cannot or choose not to use HRT, and for those who want a natural whole-body approach that works with their biology.
A Formulation Built for
Precision and Purpose
Sovereign ECS delivers a complete clinical product range built around the broad-spectrum phytocannabinoid suppository at its centre, complemented by topical and sublingual formats developed and owned outright by Sovereign ECS. Five years of research and development, including an active pilot study with real participants, underpin the formulation design.
All Sovereign ECS suppositories are formulated for rectal administration, taken every other day across the pack supply. Rectal delivery bypasses first-pass liver metabolism and delivers active phytocannabinoids directly to the richly-receptored pelvic region for high bioavailability and full-spectrum ECS activation.
| SKU | Route | Format | mg / Unit | Total Potency | MSRP | Target |
|---|---|---|---|---|---|---|
| Menstrual Support PMS | Rectal Only | 15 suppositories, 1-month | 150 mg | 2,250 mg | $109 | Women 18–45, cyclical symptoms |
| Menstrual Support, 3-month | Rectal Only | 45 suppositories, 3-month | 150 mg | 6,750 mg | $285 | Quarterly subscriber commit |
| Peri/Menopause | Rectal Only | 15 suppositories, 1-month | 120 mg | 1,800 mg | $99 | Women 40–60, hormonal transition |
| Peri/Menopause, 3-month | Rectal Only | 45 suppositories, 3-month | 120 mg | 5,400 mg | $255 | Quarterly subscriber commit |
| SKU | Format | MSRP | Target |
|---|---|---|---|
| Topical | 2oz unit | $53 | Localised pain, inflammation, skin support |
| Sublingual | 30ml, 1-month supply | $48 | Daily systemic ECS support |
The 3-month suppository packs reduce per-month cost for the customer and reduce shipping and fulfilment costs for the business, supporting the natural customer journey from monthly trial to quarterly commit once efficacy is established.
Regulatory and manufacturing position. Sovereign ECS suppositories are formulated from federally legal hemp-derived broad-spectrum phytocannabinoids containing no detectable THC, sitting within the 2018 Farm Bill framework that governs hemp-derived products in the United States. Production runs through in-house lab capacity at launch, transitioning to a vetted GMP-certified co-packer at the 2,000-pack monthly threshold. All raw cannabinoid inputs are sourced from suppliers providing batch-level Certificates of Analysis verified by ACS Laboratory. Payment processing, e-commerce, and shipping are handled through providers with established hemp-product compliance. The category remains state-by-state nuanced; Sovereign ECS ships to all states permitting hemp-derived broad-spectrum products and monitors regulatory developments through dedicated counsel.
More Than a Product.
A Complete Ecosystem.
Sovereign ECS operates on two tracks. The full product range is available to any customer at MSRP through the public storefront. The membership platform sits alongside this, giving members preferred product pricing and access to a structured women's wellness ecosystem delivered through a members-only digital platform. The product is the anchor. The membership is the moat. This model dramatically increases customer lifetime value, supports retention, and creates a category of loyalty that product-only businesses cannot replicate.
Members log in to the Sovereign ECS members-only website, where the six pillars are delivered as a continuously updated content library — monthly modules of education, practitioner guidance, recipes, practices, and curated product recommendations across the full ecosystem of women's wellness. Members order suppositories, topicals, and sublingual at member pricing through the same platform, with delivery options spanning monthly subscription, quarterly commit, and one-off purchase.
Three commitment tiers. One compounding relationship.
Members choose the commitment level that fits their stage of the journey, with stronger incentives at deeper commits. The structure is designed to support the natural arc from monthly trial through quarterly confidence to annual partnership.
| Tier | Price | Effective Monthly | Saving vs Monthly |
|---|---|---|---|
| Monthly | $30 / month | $30.00 | — |
| Quarterly | $80 / quarter | $26.67 | 11% |
| Annual | $300 / year | $25.00 | 17% |
The Sovereign ECS product range is openly available to any customer at MSRP. The membership platform sits alongside, delivering preferred pricing and the full women's wellness ecosystem to members.
| Experience | Non-Member | Member |
|---|---|---|
| Purchase suppositories, topicals, sublingual | At MSRP | At member pricing (15–20% off) |
| Access 3-month suppository packs | At MSRP | At member pricing |
| Members-only website and content library | — | Full access |
| Six pillars of monthly guidance | — | Full access |
| Educational content, recipes, practices | — | Continuously updated library |
| Practitioner orientation consultation | — | Annual tier signup bonus |
| Welcome bundle on signup | — | Annual tier ($101 value) |
| Month-7 retention pack | — | Annual tier (up to $93 value) |
| Locked-in pricing | — | Annual tier, 12 months |
| Priority access to new product launches | — | All members |
All members access the Sovereign ECS product range at member pricing. The structure reflects member status as platform participants rather than retail customers.
| Product | MSRP | Member Price | Member Saves |
|---|---|---|---|
| Menstrual Suppository, 1-month | $109 | $93 | 15% |
| Menstrual Suppository, 3-month | $285 | $242 | 15% |
| Peri/Menopause Suppository, 1-month | $99 | $84 | 15% |
| Peri/Menopause Suppository, 3-month | $255 | $217 | 15% |
| Topical, 2oz | $53 | $42 | 20% |
| Sublingual, 30ml | $48 | $38 | 20% |
Annual member signup bonuses. Members joining at the annual tier receive a welcome bundle on signup (one topical and one sublingual at no charge, retail value $101), a complimentary 1-month suppository pack at month 7 as a retention reward (retail value up to $93), locked-in pricing for the full 12 months protecting against any future MSRP changes, a complimentary practitioner orientation consultation, and priority access to new product launches ahead of the wider member base. The combined Year 1 added value typically exceeds $200 in product and benefits, on top of the platform itself.
Subscription membership fundamentally changes the unit economics.
A one-time product purchase has a single revenue event. A membership subscriber generates recurring monthly revenue across an average relationship that, for women's wellness platforms, extends 18 to 36 months or more. Member pricing at 15 to 20 percent reflects platform participation rather than retail markup, and the per-unit margin on each product remains strong at every tier. The compounding economics come from the combination of recurring subscription revenue, repeat product purchases at protected margins, and the natural progression of members from monthly trial through quarterly commitment to annual partnership. A full-stack annual member purchasing the quarterly suppository pack alongside monthly topical and sublingual generates over $1,000 in annual gross contribution, before premium tier upgrades or affiliate income are counted.
Why Sovereign ECS
Cannot Be Easily Replicated
The women's hormonal wellness market is growing rapidly but remains dominated by single-symptom products, low-potency CBD offerings, and generic subscription boxes with no clinical anchor. Sovereign ECS occupies a position no current competitor holds — a precision-formulated, scientifically grounded ECS activation product embedded within a holistic membership platform.
| Brand / Product | mg / Unit | Cannabinoid Profile | MSRP | $/mg | Membership |
|---|---|---|---|---|---|
| Sovereign ECS — Menstrual Us | 150 mg | 12 cannabinoids, broad-spectrum | $109 | $0.05 | Full platform |
| Sovereign ECS — Peri/Menopause Us | 120 mg | 12 cannabinoids, broad-spectrum | $99 | $0.06 | Full platform |
| Foria Relief Melts | 100 mg | CBD only | $48 | $0.06 | None |
| Hello Again | ~25 mg | Full-spectrum with THC | $55 | $0.28 | None |
| Healing Rose | 100 mg | CBG and CBD only | $150 | $0.05 | None |
No competitor combines clinical-grade cannabinoid potency with a holistic membership platform. Sovereign ECS is 4 to 6 times better value per mg than Hello Again and significantly broader in cannabinoid profile than all current alternatives.
The calculation. Hello Again delivers approximately 25mg per unit at $55, or $0.28 per mg. Sovereign ECS Menstrual at 150mg per unit at $109 equals $0.05 per mg, 5.6 times better value. Sovereign ECS Peri/Menopause at 120mg per unit at $99 equals $0.06 per mg, 4.7 times better value.
The Pilot Study —
Results Being Collected Now
Sovereign ECS is not a concept. The formulation is made. Product has been delivered to a real pilot study cohort of women, currently working through a structured programme with baseline and follow-up questionnaires capturing changes across eight key symptom categories.
Participants complete a structured protocol using 15 Sovereign ECS suppositories administered every other day, with questionnaires at baseline, week 1, week 2, week 3, and week 4 post-completion. The study is measuring changes across sleep quality, mood and emotional resilience, hot flushes and temperature regulation, joint comfort and physical ease, energy and vitality, cognitive clarity, libido and vaginal comfort, and overall wellbeing.
Seven women are enrolled across the perimenopausal, menopausal, and pre-menopausal stages, aged 35 to 54. All signed informed consent. Six questionnaire responses have been collected across weeks one and two of the protocol, with further check-ins ongoing through week four post-completion.
Six Responses In.
The Signal Is Already Clear.
With six questionnaire responses collected across weeks one and two of the pilot, early patterns are emerging across all twelve symptom categories. Scores are reported on a 1 to 10 scale where higher scores indicate improvement relative to baseline. All six respondents reported noticing change in a positive direction. Four of six expressed confidence the product is working for them. Five of six used the suppositories consistently throughout the period.
| Symptom Category | Avg Score / 10 | Responses | Signal |
|---|---|---|---|
| Stress Management | 6.5 / 10 | 6 | Strongest early signal |
| Mood Stability | 6.3 / 10 | 6 | Consistent across cohort |
| Overall Quality of Life | 6.3 / 10 | 6 | Consistent across cohort |
| Emotional Resilience | 6.3 / 10 | 6 | Consistent across cohort |
| Energy Levels | 6.0 / 10 | 6 | Emerging |
| Joint Comfort | 5.8 / 10 | 6 | Emerging |
| Night Sweats / Temperature | 5.7 / 10 | 6 | Emerging |
| Libido | 5.7 / 10 | 6 | Emerging |
| Cognitive Clarity | 5.5 / 10 | 6 | Early stage |
| Sleep Quality | 5.3 / 10 | 6 | Early stage |
| Hot Flush Frequency | 5.3 / 10 | 6 | Early stage |
| Vaginal Comfort | 5.2 / 10 | 6 | Early stage |
All scores are self-reported improvement ratings on a 1–10 scale relative to individual baseline. Data collected at weeks 1 and 2 only — the full protocol runs through week 4 post-completion. Scores in the 5–6 range at this stage are consistent with or above comparable early-phase outcomes for natural ECS support products. Categories rated 6.3+ represent the strongest early signals.
The qualitative signal reinforces the numbers.
"I feel brighter — if that is a response."
"I have been under a tremendous amount of extra stress and feel like the products have helped me stay functional. Some sleep improvement is noted."
"Overall much better than typical pre-menstrual symptoms."
"I feel like I handled my stressors better than I would have without it."
Context for investors: These are early-stage week 1 and week 2 scores. ECS support compounds accumulate systemic effect over time — weeks 3 and 4, and the post-completion follow-up questionnaires, are where the most significant outcome data is expected to emerge. The early signal in stress management, mood, and emotional resilience is consistent with what the science of ECS modulation would predict as the first areas of measurable response. Full results will be shared with investors as the cohort completes the protocol.
Two Raises. Two Stages.
A Clear Path to Scale.
Sovereign ECS is structured around a two-stage capital approach. The first raise is purely operational — getting the business live, the product manufactured, and the first members subscribed using existing in-house lab capacity. The second raise is a social media and organic growth engine that drives meaningful customer acquisition at scale. Both are intentionally modest relative to the returns they are designed to unlock.
$10,000 – $30,000 to get Sovereign ECS live
This raise covers the essentials to move from pilot to commercial operation. At $10,000 the business launches in lean bootstrap mode using existing in-house lab capacity producing up to 60 packs per day. At $30,000 the launch is fuller — more initial inventory, a complete website and membership platform, and professional packaging ready for first subscribers. No co-packer is required at this stage. The business is cash-generative from the first sales at a 71–73% gross margin.
| Use of Operational Funds | $10k Scenario | $20k Scenario | $30k Scenario |
|---|---|---|---|
| Ingredients and initial batch production | $4,500 | $8,000 | $12,000 |
| Packaging, seals, boxes, labels | $2,000 | $3,500 | $5,000 |
| Website and membership platform | $1,500 | $4,000 | $6,500 |
| Legal, compliance, and IP basics | $1,000 | $2,500 | $4,000 |
| Working capital and contingency | $1,000 | $2,000 | $2,500 |
| Initial packs producible from raise | ~150 packs | ~280 packs | ~420 packs |
| Estimated Year 1 Revenue (organic only) | $45,000 – $70,000 | $85,000 – $130,000 | $130,000 – $200,000 |
| Estimated break-even timeline | ~10 months | ~8 months | ~6 months |
Revenue projections based on in-house production only, organic word-of-mouth and pilot network conversions, 40% trial-to-repeat rate, and average blended MSRP of $104 per pack. COGS of $29 per pack yields 72% gross margin. Reinvested gross profit funds ongoing batch production from month 2 onward.
$150,000 – $500,000 to fuel organic acquisition and scale
Once operational and generating initial revenue, the growth raise funds an education-led social media strategy across Instagram, TikTok, and Facebook — the primary acquisition channels for the Sovereign ECS target demographic. This is organic influencer and content-led marketing that builds brand authority and community, not paid advertising that disappears when the budget stops. At $150,000 this funds 12 to 18 months of consistent content, influencer partnerships, and community building. At $500,000 it funds a full two-to-three year acquisition engine that drives subscriber numbers to co-packer transition threshold, where COGS drop 20 to 30% and margins expand significantly.
| Growth Scenario | Social Raise | Year 1 Revenue | Year 2 Revenue | Year 3 Revenue | Gross Margin | Break-Even |
|---|---|---|---|---|---|---|
| Organic Bootstrap Only | $0 | $70K – $200K | $200K – $500K | $400K – $1.0M | 71–73% | 6–10 months |
| Partial Growth Raise | $150,000 | $300K – $550K | $700K – $1.3M | $1.6M – $2.6M | 73–76% | ~8 months |
| Full Growth Raise | $500,000 | $700K – $1.1M | $1.7M – $2.5M | $3.5M – $5.0M | 76–80% | ~6 months |
Growth scenarios modelled on 40–50% trial-to-repeat conversion, $80–$120 blended CAC for social-funded scenarios, and co-packer transition at 2,000+ monthly packs enabling 20–30% COGS reduction from Year 2. Full growth scenario targets 3–5x investor return within 36 months. Comparable DTC CBD brand benchmarks: cbdMD 61–66% gross margin; Care/of 65–75%; Hims and Hers 70%+.
Where the growth capital goes.
The growth raise is structured to fund a content-led organic acquisition engine, not a paid-media campaign that disappears the moment the budget stops. Allocation is intentionally weighted toward durable assets, content, community, and member infrastructure, that continue working long after the deployment period.
| Allocation Category | % of Raise | $150K Scenario | $500K Scenario |
|---|---|---|---|
| Content production (video, photo, editorial) | 32% | $48,000 | $160,000 |
| Influencer and practitioner partnerships | 22% | $33,000 | $110,000 |
| Member platform, CRM, subscription infrastructure | 14% | $21,000 | $70,000 |
| Founder bandwidth and key hires | 12% | $18,000 | $60,000 |
| Paid social testing and amplification | 10% | $15,000 | $50,000 |
| Inventory scale and packaging upgrade | 6% | $9,000 | $30,000 |
| Legal, compliance, and IP protection | 4% | $6,000 | $20,000 |
Allocations are directional and may shift as channel performance data accumulates. The 10% paid social line is deliberately small at this stage, used for amplification of high-performing organic content and audience testing, not as the primary acquisition channel.
On the $80 to $120 CAC assumption. Comparable DTC women's wellness brands report blended CACs in the $60 to $150 range when organic content is the primary engine and paid social is used selectively. Hims and Hers reported $60 to $90 in their growth phase; Care/of reported $120 to $140 in the same window. The Sovereign ECS model is built on the lower-cost end of this range because the membership structure compounds lifetime value across multiple revenue streams. A single annual member purchasing the quarterly suppository pack generates approximately $300 in subscription revenue and $868 in product revenue over Year 1, yielding gross contribution of roughly $1,000 net of product COGS and signup incentives. Against a $100 CAC, that represents a 10x first-year contribution-to-acquisition ratio on the single-product member, rising further across the 18 to 36 month average member relationship and substantially higher for multi-product members. Actual CAC will be published quarterly to investors as the data accumulates.
From pilot conversions to a 1,000-member platform.
The subscription model drives the long-run economics. The table below reconciles the per-pack revenue projections with the member-base build expected to support them under the full growth raise scenario.
| Milestone | Active Members | Monthly Subscription ARR | Active Pack Volume / Month | Cumulative Revenue |
|---|---|---|---|---|
| Month 6 | 50 | $16,200 | ~120 packs | ~$80,000 – $110,000 |
| Month 12 | 250 | $81,000 | ~400 packs | ~$400,000 – $550,000 |
| Month 18 — co-packer transition | 600 | $194,400 | ~900 packs | ~$900,000 – $1.3M |
| Month 24 | 1,000 | $324,000 | ~1,500 packs | ~$1.8M – $2.4M |
| Month 36 | 1,800 – 2,200 | $583K – $713K | ~2,800 packs | ~$3.5M – $5.0M |
Membership ARR calculated at a blended $27 per month, reflecting expected mix across monthly ($30), quarterly ($26.67 equivalent), and annual ($25 equivalent) tiers. Pack volume reflects combined member subscriptions and one-off non-member purchases at MSRP. Co-packer transition triggered at the 600-member mark when monthly pack volume reaches 2,000+ including member orders. Subscriber retention modelled at 18 to 36 month average, consistent with comparable women's wellness platforms. Cumulative revenue figures blend subscription ARR, member-priced product sales, and non-member MSRP sales. Schedule assumes full $500,000 growth raise; partial raise extends timeline by 6 to 12 months.
Multiple routes under active consideration.
The 3 to 5x target return within 36 months is supported by several realistic exit pathways currently under review with the senior team. Strategic acquisition, Series A at stepped-up valuation, and cash distribution from a mature margin-positive business are all viable structures for a business of this profile. Final exit framework and investor liquidity terms will be confirmed and shared with Founding Circle and Growth Raise participants ahead of close.
Science-Led.
Purpose-Driven.
"I spent 25 years in pharmaceutical and biotech development — working on autoimmune disease and cancer treatments at the highest levels of the industry. In 2017, I had a stroke. That event changed everything."
In the years that followed, Barry turned to the science his medical and pharmaceutical training had never introduced him to: the endocannabinoid system, the gut-brain axis, and the natural intelligence of the body when properly supported. The ECS had been quietly removed from medical curricula long before his generation entered the industry, leaving an entire field of physiology unfamiliar to both patients and practitioners. What he found there was extraordinary.
Sovereign ECS was born from that research and from conversations with women who had tried everything the conventional system offered and were still searching for something natural, sustainable, and aligned with how their bodies actually work. Barry brings a rare combination of genuine pharmaceutical science depth, five years of ECS-specific formulation research, and the conviction that comes from having experienced the limitations of conventional medicine firsthand.
Two operators joining at founding level.
The founder is being joined by two senior operators each taking equity at founding level. Profiles and full attribution available to qualified investors under NDA.
Three Entry Points.
One Compounding Opportunity.
Sovereign ECS offers three distinct participation opportunities, structured to meet investors where they are. The operational raise gets the business live. The Founding Circle builds the early growth runway and welcomes warm-network partners introduced through our senior team. The growth raise funds full-scale acquisition. Investors may participate in one, two, or all three stages. All are structured as equity and SAFE agreements designed to align long-term incentives and maximise upside at each stage.
A defined cohort, between operational launch and full growth.
The operational raise is intentionally modest, enough to get Sovereign ECS live and cash-generative. The growth raise is structured for institutional and lead-investor capital. Between these two sits a defined cohort of investors who recognise the opportunity early, bring meaningful capital at $30,000 to $150,000, and want a position that reflects entering before the full growth round. The Founding Circle is that cohort. It funds the early growth activity, content production, founder bandwidth, and initial influencer seeding, that bridges the business from operational launch to the full social acquisition engine. Members of the Founding Circle hold a preferred position relative to the growth raise and a defined relationship with the founder through the scaling phase.
The social media growth raise of $150,000 to $500,000 then funds the acquisition engine that takes a live, margin-positive product business to co-packer scale and beyond. The model is capital-efficient by design, high gross margins from launch mean every dollar works harder than in most comparable consumer wellness businesses.
What Could Go Wrong.
And How We Are Positioned.
Sophisticated investors expect a clear-eyed account of risk. The following are the material risks Sovereign ECS has identified, alongside the structural choices that mitigate each.
This list is not exhaustive. Investors are encouraged to raise any further concerns directly with the founder. Sovereign ECS maintains a position of transparency on operational, regulatory, and clinical matters and will share supporting documentation under NDA where useful.